Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery

No abstract is available for this paper.

• Publication year

  2017

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2017-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.13243PMID 28121368PMCID PMC5465330
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery

  2017cited by this paper
• Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

  2015cited by this paper
• Thromboembolic events in bariatric surgery: a large multi-institutional referral center experience

  2015cited by this paper
• The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

  2015cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

  2015cited by this paper
• ASMBS updated position statement on prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients.

  2013cited by this paper
• Complication Rates After Hip or Knee Arthroplasty in Morbidly Obese Patients

  2013cited by this paper
• Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

  2013cited by this paper
• Is the ideal anticoagulant a myth?

  2012cited by this paper
• Predicting Risk for Venous Thromboembolism With Bariatric Surgery: Results From the Michigan Bariatric Surgery Collaborative

  2012cited by this paper
• Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.

  2012cited by this paper
• Obesity and pulmonary embolism: the mounting evidence of risk and the mortality paradox.

  2011cited by this paper
• Obesity and venous thrombosis: a review.

  2011cited by this paper
• Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of Excellence Participants: analysis of the Bariatric Outcomes Longitudinal Database.

  2011cited by this paper
• Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis.

  2009cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

  2009cited by this paper
• Cardiovascular Risk Factors and Venous Thromboembolism: A Meta-Analysis

  2008cited by this paper
• Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature

  2008cited by this paper
• Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

  2008cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

  2008cited by this paper
• Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery

  2008cited by this paper
• Incidence of deep vein thrombosis in morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass.

  2008cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

  2008cited by this paper
• Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

  2008cited by this paper
• Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects

  2007cited by this paper
• The metabolic syndrome.

  2005cited by this paper
• Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59‐7939, an oral, direct factor Xa inhibitor

  2005cited by this paper
• The metabolic syndrome.

  2003cited by this paper
• Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass.

  2003cited by this paper
• Plasminogen activator inhibitor‐1, inflammation, obesity, insulin resistance and vascular risk

  2003cited by this paper
• Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems

  2003cited by this paper
• Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines.

  2001cited by this paper

• Efficacy and Safety of Direct Oral Anticoagulants (DOACs) Versus Enoxaparin For Extended Thromboprophylaxis Following Sleeve Gastrectomy

  2026cites this paper
• Effects of sleeve gastrectomy on rivaroxaban pharmacokinetics, efficacy, and safety.

  2026cites this paper
• Obesity and Venous Thromboembolism: Mechanisms, Clinical Implications, and Prevention Strategies With a Focus on Bariatric Surgery

  2025cites this paper
• Efficacy and safety of direct oral anticoagulants (DOACs) for postoperative thromboprophylaxis in patients after bariatric surgery: a systematic review and meta-analysis.

  2025cites this paper
• Pharmacokinetics after bariatric surgery: adverse effects and drug safety issues in bariatric patients

  2025cites this paper
• Transforming Treatment: The Impact of Bariatric Surgery on Oral Drug Absorption.

  2025cites this paper
• Anticoagulation in obese patients: challenges and strategies

  2025cites this paper
• Effects of Bariatric Surgery on the Pharmacokinetics of Cardiovascular Drugs: A Systematic Review and Meta-Analysis

  2025cites this paper
• Bioavailability of Orally Administered Drugs After Bariatric Surgery

  2024cites this paper
• Assessment of rivaroxaban as venous thromboembolism prophylaxis after gastric bypass surgery

  2024cites this paper
• Full Dose Rivaroxaban in Patients with a History of Bariatric Surgery: Bridging the Knowledge Gap through a Phase 1 Study.

  2024cites this paper
• Medication and supplement pharmacokinetic changes following bariatric surgery: A systematic review and meta‐analysis

  2024cites this paper
• Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease

  2024cites this paper
• Intrinsic coagulant potential modulates anticoagulant efficacy of rivaroxaban.

  2024cites this paper
• Extended Post Discharge Prophylaxis for Venous Thromboembolism Prevention After Bariatric Surgery

  2024cites this paper
• [Bariatric surgery and drugs: Review of the literature and Adverse Drug Reactions analysis in French National Pharmacovigilance Database].

  2024cites this paper
• DOACs: A perfect fit for patients with bariatric surgery?

  2024cites this paper
• Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery

  2023cites this paper
• The Effects of Bariatric Surgery on Pharmacokinetics of Drugs: a Review of Current Evidence

  2023cites this paper
• Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data

  2023cites this paper
• Assessing the knowledge of medical undergraduates on oral anticoagulation therapy

  2023cites this paper
• Impact of Bariatric Surgery in the Short and Long Term: A Need for Time-Dependent Dosing of Drugs

  2023cites this paper
• Practical Issues with Using Direct Oral Anticoagulant After Bariatric Metabolic Surgery

  2023cites this paper
• Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism

  2022cites this paper
• Outcomes with direct acting oral anticoagulants in patients with a history of bariatric surgery: a retrospective cohort study

  2022cites this paper
• Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery

  2022cites this paper
• Direct oral anticoagulants after bariatric surgery—What is the evidence?

  2022cites this paper
• Mon sommeil, mon coeur, mes vaisseaux

  2022cites this paper
• The American Society for Metabolic and Bariatric Surgery (ASMBS) updated position statement on perioperative venous thromboembolism prophylaxis in bariatric surgery.

  2021cites this paper
• Direct Oral Anticoagulants in the Treatment of Venous Thromboembolism: Use in Patients with Advanced Renal Impairment, Obesity, or Other Weight-Related Special Populations

  2021cites this paper
• Recurrent Thrombi in an Obese Patient With History of Bariatric Surgery Despite Anti-Xa Therapy

  2021cites this paper
• The importance of use of appropriate anticoagulant in atrial fibrillation after gastric bypass surgery

  2021cites this paper
• Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review.

  2021cites this paper
• Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series

  2021cites this paper
• Effect of laparoscopic sleeve gastrectomy on drug pharmacokinetics

  2021influential citation
• The Effects of Bariatric Surgery and Gastrectomy on the Absorption of Drugs, Vitamins, and Mineral Elements

  2021cites this paper
• The APB study: apixaban pharmacokinetics in bariatric patients before to 1 year after vertical sleeve gastrectomy or Roux-en-Y gastric bypass.

  2021cites this paper
• How I Treat Obese Patients with Oral Anticoagulants.

  2020cites this paper
• Oral drug dosing following bariatric surgery: General concepts and specific dosing advice

  2020cites this paper
• The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations

  2020cites this paper
• Impact of bariatric surgery on oral anticoagulants pharmacology, and consequences for clinical practice: a narrative review

  2020cites this paper
• Does One Dose Really Fit All? On the Monitoring of Direct Oral Anticoagulants: A Review of the Literature

  2020cites this paper
• Should we monitor the direct oral anticoagulants?

  2020cites this paper
• Pharmacokinetic changes post–bariatric surgery: A scoping review

  2020cites this paper
• Hyper-coagulability in obese patients accurately identified by combinations of global coagulation assay parameters.

  2020cites this paper
• Gastrointestinal and liver diseases and atrial fibrillation: a review of the literature

  2019cites this paper
• Embolie pulmonaire et agénésie de veine cave inférieure : une association inhabituelle

  2019cites this paper
• [Pulmonary embolism and inferior vena cava agenesis: An unusual association].

  2019cites this paper
• The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review

  2019cites this paper
• Rivaroxaban for prevention and treatment of venous thromboembolism.

  2019cites this paper
• Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis.

  2018cites this paper
• The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study.

  2018cites this paper
• Systematic review of drug bioavailability following gastrointestinal surgery

  2018cites this paper
• Effect of Rivaroxaban on thrombin generation in vivo. A study in obese patients

  2018cites this paper
• Anticoagulant drug choice in patients who have had bariatric surgery - Presently, DOACs are not the preferred choice.

  2018cites this paper
• Direct oral anticoagulants after bariatric surgery: To use or not to use.

  2018cites this paper
• Reply to: The effect of bariatric surgery on direct-acting oral anticoagulant drug levels.

  2018cites this paper
• The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation.

  2017cites this paper
• Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery

  2017cites this paper
• The impact of body weight on rivaroxaban pharmacokinetics

  2017cites this paper
• Influences of Obesity and Bariatric Surgery on the Clinical and Pharmacologic Profile of Rivaroxaban.

  2017cites this paper
• The effect of bariatric surgery on direct-acting oral anticoagulant drug levels.

  2017cites this paper